Status:
RECRUITING
Omega-3 Supplementation for Pediatric Migraine
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
Nutrition Obesity Research Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Migraine
Eligibility:
All Genders
10-17 years
Phase:
NA
Brief Summary
The purpose of the study is to assess the biochemical and clinical effects of omega-3 polyunsaturated fatty acid (PUFA) supplementation in youth suffering from migraine, including its effects on migra...
Detailed Description
Omega-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), hold potential therapeutic benefit for pediatric migraine due to their potent anti...
Eligibility Criteria
Inclusion
- Males and females between the ages of 10 and 17 years
- Parent consent and subject assent
- Diagnosis of migraine based on the third edition of the International Classification of Headache Disorders (ICHD-3) criteria
Exclusion
- Known allergy to fish or seafood
- Current use of an omega-3 dietary supplement
- Significant neurological or psychiatric disorders or developmental delays
- Non-English speaking
- Allergy to coconut
- Pregnancy
Key Trial Info
Start Date :
April 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06899074
Start Date
April 17 2025
End Date
March 1 2026
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599